The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
Marking World Asthma Day 2026, doctors sounded the alarm over a steady surge in respiratory illnesses
The private funding rose 38% amid growing international collaborations and CDMO demand
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Subscribe To Our Newsletter & Stay Updated
